Show simple item record

dc.contributor.authorBayliss, George P.en_US
dc.contributor.authorWeinrauch, Larry A.en_US
dc.contributor.authorGleason, Ray E.en_US
dc.contributor.authorLee, Annette T.en_US
dc.contributor.authorD'Elia, John A.en_US
dc.date.accessioned2015-07-13T18:46:51Z
dc.date.issued2013en_US
dc.identifier.citationBayliss, George P., Larry A. Weinrauch, Ray E. Gleason, Annette T. Lee, and John A. D'Elia. 2013. “Do biologic markers predict cardiovascular end points in diabetic end-stage renal disease? A prospective longitudinal study.” Clinical Kidney Journal 6 (6): 599-603. doi:10.1093/ckj/sft116. http://dx.doi.org/10.1093/ckj/sft116.en
dc.identifier.issn2048-8505en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:17295621
dc.description.abstractBackground: Diabetic patients on hemodialysis are at high risk of death from cardiovascular disease, and research has suggested that various biologic markers of inflammation, oxidative stress and hemostasis may give added value to clinical information for predicting cardiovascular event (CVE)-free survival. This information could be particularly important in evaluating this population for renal transplant, given the scarcity of organs. We hypothesized that in diabetic patients undergoing renal replacement therapy (RRT) these biologic markers would prove useful in predicting event-free follow-up in a prospective study. Methods: One hundred and fifty diabetic (76 type 1, 74 type 2) and 27 non-diabetic stable RRT patients were followed for 0.04–13.69 years for CVE (myocardial infarction, coronary arterial intervention, peripheral arterial bypass or amputation, cerebrovascular accident or carotid artery intervention), cardiac and all-cause mortality. Measured biologic markers of inflammation included the following: Il-6, C reactive protein, fibrinogen; of hemostasis: fibrinogen, plasminogen activator inhibitor (PAI), fibrinolytic activity, von Willebrand factor VII (vWF), platelet-selectin, viscosity and of oxidative stress: advanced glycated end products and antibody to oxidized low-density lipoprotein. For each, upper versus lower tertiles were compared for duration of event-free follow-up. Results: Cardiovascular events prior to study entry occurred in 51.3% of DM1, 54.0% of DM2 and 25.9% of DM0 patients. Subsequent cardiovascular events were noted in 31.6% of DM1, 45.9% of DM2 and 11.1% of DM0 patients. All mean levels of biologic markers at baseline were abnormal (P < 0.05). Conclusions: In this RRT population, all biologic marker levels except PAI did not improve clinical prediction of events.en
dc.language.isoen_USen
dc.publisherOxford University Pressen
dc.relation.isversionofdoi:10.1093/ckj/sft116en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438364/pdf/en
dash.licenseLAAen_US
dc.subjectbiologic markersen
dc.subjectcardiovascular eventsen
dc.subjectdiabetesen
dc.subjectplasminogen activator inhibitoren
dc.subjectrenal replacement therapyen
dc.titleDo biologic markers predict cardiovascular end points in diabetic end-stage renal disease? A prospective longitudinal studyen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalClinical Kidney Journalen
dash.depositing.authorWeinrauch, Larry A.en_US
dc.date.available2015-07-13T18:46:51Z
dc.identifier.doi10.1093/ckj/sft116*
dash.contributor.affiliatedD'Elia, John
dash.contributor.affiliatedWeinrauch, Larry
dash.contributor.affiliatedGleason, Ray


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record